Karuna Therapeutics, Inc.
KRTXNASDAQHealthcare
$329.83
+$0.09(+0.03%)
Market Cap$12.6B
P/E Ratio—
52W High$329.99
52W Low$158.375
Karuna Therapeutics, Inc. (KRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KRTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 2, 2024EPS Actual
-$2.80
Est. -$3.06 · +8.5%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 2, 2024
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
KRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2024 | May 2, 2024 | -$3.06 | -$2.80 | +8.5% | — | $0.00B | — |
| ▼ Q1 FY2024 | Feb 22, 2024 | -$2.64 | -$3.01 | -14.0% | — | $0.00B | — |
| ▼ Q4 FY2023 | Nov 2, 2023 | -$2.74 | -$3.16 | -15.3% | — | $0.00B | — |
| — Q3 FY2023 | Aug 3, 2023 | -$2.76 | -$2.75 | +0.4% | — | $0.00B | — |
| ▲ Q2 FY2023 | May 4, 2023 | -$2.86 | -$2.80 | +2.1% | $0.00B | — | — |
| — Q1 FY2023 | Feb 23, 2023 | -$2.23 | -$2.22 | +0.5% | $0.01B | $0.00B | +73790.5% |
| ▼ Q4 FY2022 | Nov 3, 2022 | -$1.99 | -$2.38 | -19.6% | $0.00B | $0.00B | -91.2% |
| ▼ Q3 FY2022 | Aug 8, 2022 | -$2.02 | -$2.17 | -7.4% | $0.01B | — | — |
Q2 FY2024
May 2, 2024Beat
EPS Actual
-$2.80
EPS Est.
-$3.06
EPS Surpr.
+8.5%
Revenue
—
Q1 FY2024
Feb 22, 2024Miss
EPS Actual
-$3.01
EPS Est.
-$2.64
EPS Surpr.
-14.0%
Revenue
—
Q4 FY2023
Nov 2, 2023Miss
EPS Actual
-$3.16
EPS Est.
-$2.74
EPS Surpr.
-15.3%
Revenue
—
Q3 FY2023
Aug 3, 2023
EPS Actual
-$2.75
EPS Est.
-$2.76
EPS Surpr.
+0.4%
Revenue
—
Q2 FY2023
May 4, 2023Beat
EPS Actual
-$2.80
EPS Est.
-$2.86
EPS Surpr.
+2.1%
Revenue
$0.00B
Q1 FY2023
Feb 23, 2023
EPS Actual
-$2.22
EPS Est.
-$2.23
EPS Surpr.
+0.5%
Revenue
$0.01B
Q4 FY2022
Nov 3, 2022Miss
EPS Actual
-$2.38
EPS Est.
-$1.99
EPS Surpr.
-19.6%
Revenue
$0.00B
Q3 FY2022
Aug 8, 2022Miss
EPS Actual
-$2.17
EPS Est.
-$2.02
EPS Surpr.
-7.4%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-1.64 | $-1.64 | $-1.64 | 3 |
| Q3 FY2025 | $-2.01 | $-2.01 | $-2.01 | 3 |
| Q2 FY2025 | $-2.33 | $-2.33 | $-2.33 | 3 |
| Q1 FY2025 | $-2.62 | $-2.62 | $-2.62 | 3 |
| Q4 FY2024 | $-2.05 | $-2.05 | $-2.05 | 2 |
| Q3 FY2024 | $-3.17 | $-3.17 | $-3.17 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2024 | May 2, 2024 | +8.5% | $329.83 | — | — |
| ▼ Q1 FY2024 | Feb 22, 2024 | -14.0% | $318.94 | $319.38 | +0.14% |
| ▼ Q4 FY2023 | Nov 2, 2023 | -15.3% | $173.18 | $169.14 | -2.33% |
| ▲ Q3 FY2023 | Aug 3, 2023 | +0.4% | $197.70 | $186.79 | -5.52% |
| ▲ Q2 FY2023 | May 4, 2023 | +2.1% | $210.40 | $206.45 | -1.88% |
| ▲ Q1 FY2023 | Feb 23, 2023 | +0.5% | $190.11 | $191.56 | +0.76% |
| ▼ Q4 FY2022 | Nov 3, 2022 | -19.6% | $217.66 | $222.45 | +2.20% |
| ▼ Q3 FY2022 | Aug 8, 2022 | -7.4% | $140.36 | $241.19 | +71.84% |
Q2 FY2024—
Report Date
May 2, 2024
EPS Beat/Miss
+8.5%
Price Before
$329.83
Price After
—
Q1 FY2024+0.14%
Report Date
Feb 22, 2024
EPS Beat/Miss
-14.0%
Price Before
$318.94
Price After
$319.38
Q4 FY2023-2.33%
Report Date
Nov 2, 2023
EPS Beat/Miss
-15.3%
Price Before
$173.18
Price After
$169.14
Q3 FY2023-5.52%
Report Date
Aug 3, 2023
EPS Beat/Miss
+0.4%
Price Before
$197.70
Price After
$186.79
Q2 FY2023-1.88%
Report Date
May 4, 2023
EPS Beat/Miss
+2.1%
Price Before
$210.40
Price After
$206.45
Q1 FY2023+0.76%
Report Date
Feb 23, 2023
EPS Beat/Miss
+0.5%
Price Before
$190.11
Price After
$191.56
Q4 FY2022+2.20%
Report Date
Nov 3, 2022
EPS Beat/Miss
-19.6%
Price Before
$217.66
Price After
$222.45
Q3 FY2022+71.84%
Report Date
Aug 8, 2022
EPS Beat/Miss
-7.4%
Price Before
$140.36
Price After
$241.19
Avg Beat Reaction-2.21%
Avg Miss Reaction+17.96%
Beat Rate4 / 8 quarters
Largest Move+71.84% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KRTX ends December
Karuna Therapeutics, Inc. (KRTX) most recently reported earnings on May 2, 2024 for Q2 FY2024, posting EPS of $-2.80 — beating the analyst consensus of $-3.06 by +8.5%. The next KRTX earnings date is expected around September 1, 2026.
Each quarter, investors track KRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KRTX earnings · 5 questionsKaruna Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. KRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KRTX historically reports after market close (AMC).
KRTX earnings datewhen is KRTX earningsKRTX next earnings datewhen does KRTX report earningsKRTX earnings calendar
▸ Source: FMP · Karuna Therapeutics, Inc. SEC filings · US GAAP · Karuna Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026